N@N

Kendall Law Group Investigates Amedisys for Shareholders

^{Published on 2010-06-24 13:41:29 - Market Wire}
 

DALLAS--([ BUSINESS WIRE ])--[ Kendall Law Group ], led by a former federal judge and a former U.S. Attorney, is investigating certain officers and directors of Amedisys (NASDAQ: AMED) for possible breaches of fiduciary duty and other federal and state laws. The national securities firm seeks to determine whether Amedisys and its directors and officers breached their fiduciary duties by causing or allowing it to unfairly take advantage of the Medicare reimbursement system. Shareholders familiar with the investigation are urged to contact the Kendall Law Group for more information at 877-744-3728 or by email at [ jmckey@kendalllawgroup.com ].

"received a high number of the most profitable therapy visits, but few of the least profitable ones."

Following the publication of an April 26, 2010 Wall Street Journal article describing increased in-home visits billed to Medicare, Amedisys stock prices fell 6.5% in one day. The article pointed out that Amedisysa™ Medicare patients areceived a high number of the most profitable therapy visits, but few of the least profitable ones.a Shortly after the article was released, the Senate Finance Committee launched an investigation to adetermine whether the companies deliberately boosted the number of home therapy visits to trigger higher Medicare reimbursements.a

Kendall Law Group has the credentials and experience to pursue any type of complex securities litigation in the nation. The firm actively protects the rights of shareholders when publicly traded companies violate the law. Since leaving the bench and returning to trial work, Mr. Kendall has had tremendous success at the prosecution of patent, consumer and securities class action litigation either as lead, co-lead or liaison counsel. Shareholders are encouraged to contact attorney Jamie McKey for more information.